Agendia, Paige partner to better breast cancer treatment

By LabPulse.com staff writers

November 18, 2020 -- Genetic testing company Agendia and artificial intelligence (AI) pathology company Paige have partnered to improve planning for breast cancer treatment, with the goal of enabling faster access to genetic information for women.

The partnership enables Agendia and Paige to develop treatment planning tools that integrate the cloud-based Paige platform using genomic information from Agendia's MammaPrint and BluePrint diagnostic tests for breast cancer patients.

The goal of the partnership is to enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning, according to the companies.

MammaPrint cancer recurrence test secures reimbursement in Germany
California-based Agendia's MammaPrint 70-gene breast cancer recurrence test is set for reimbursement in Germany following a positive opinion for coverage...
FDA OK's Paige's FullFocus viewer
Artificial intelligence pathology company Paige has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FullFocus viewer for primary...
Paige raises $15M more for AI, cancer pathology
Artificial intelligence (AI) pathology company Paige has raised $15 million in additional funding from Goldman Sachs to support its efforts related...
Mammaprint maker settles Medicare fraud lawsuit for $8M
The maker of a popular genetic test that analyzes a patient's risk of breast cancer recurrence has agreed to pay an $8.25 million settlement for...
Paige raises additional funds for AI, cancer pathology
Artificial intelligence (AI) pathology company Paige has raised additional funding from Goldman Sachs to support its efforts related to cancer diagnostics...

Copyright © 2020 LabPulse.com

Last Updated ls 11/18/2020 2:24:56 PM